Latest News and Press Releases

China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALLPositive 48-Week Phase I Clinical Data of...

SHANGHAI, China and CUPERTINO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

中国上海市与加州库伯提诺市, March 21, 2018 (GLOBE NEWSWIRE) -- 西比曼生物科技集团（NASDAQ:CBMG，简称“CBMG”或“公司”） 是一家从事癌症免疫疗法和退行性疾病干细胞疗法开发的临床阶段生物制药公司。于中国杭州举办的“纳斯达克创新医药企业中国峰会暨杭州CBD论坛（CHIPS2018）”上，西比曼生物科技集团（CBMG）公司干细胞事业部（Stem...

SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

  Expanded GMP manufacturing capacity to become one of the largest in-house CAR-T manufacturers amongst leading global biopharmaceutical companiesSigned partnerships with GE Healthcare Life Sciences...

SHANGHAI, China and CUPERTINO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...

SHANGHAI, China and CUPERTINO, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development...

GE为西比曼加速CAR-T细胞治疗药物的临床试验及未来商业化进程提供生产支持西比曼上海工厂将成为全球首个采用GE医疗细胞治疗灵活生产平台（FlexFactoryTM）技术的细胞治疗产品生产设施，并配备功能完善且可扩展的细胞治疗生产能力、培训及服务 中国上海及美国加州库比蒂诺市, Jan. 20, 2018 (GLOBE NEWSWIRE) --...